Fleet Phospho-soda - Oral Sodium Phosphate
Carabin & Shaw Medical Alert
(press Play to view)
(press Play to view)
Oral Sodium Phosphate Products
The following pages discuss in detail the U.S. Food & Drug Administration's warning of possible life-threatening kidney injury. Severe kidney injuries can occur as a result of ingesting oral sodium phosphate products that include the medical condition known as acute phosphate nephropathy. This condition known as Acute Phosphate Nephropathy has been linked to the prescription and over-the-counter laxatives that include Visicol, OsmoPrep and Fleet Phospho-Soda. For some individuals these products can me deadly. Call our Law Firm for more information at 1-800-862-1260.
If you or a loved one have suffered a kidney injury after using Visicol, OsmoPrep, Fleet Phospho-Soda or any other laxative product or solution containing oral sodium phosphate, you should call our Law Firm immediately. You may be entitled to compensation for your injuries and our Law Firm can help, call 1-800-862-1260.
What is the issue?
In December 2008 the FDA notified the manufacturers of oral sodium phosphate products (OSP) that they are required to add a “Boxed Warning” to their products' labeling that warns consumers of the risk of developing acute phosphate nephropathy, a type of acute kidney injury. Some of the oral sodium phosphate products included within this warning include popular prescription OSP’s including Visicol and OsmoPrep, as well as some over-the-counter laxatives (e.g., Fleet Phospho-soda). These products are used for bowel cleansing prior to colonoscopy or other procedures.
What is Acute Phosphate Nephropathy?
Acute Phosphate Nephropathy is a form of an acute kidney injury that is associated with deposits of calcium-phosphate crystals in the renal tubules that may result in permanent renal function impairment. Acute Phosphate Nephropathy is a rare and serious adverse kidney event that has been associated with the use of Oral Sodium Phosphate or OSPs.
The occurrence of these events was previously described in an Information for Healthcare Professionals sheet and an FDA Finding and Science Paper issued in May 2006. Additional cases of acute phosphate nephropathy have been reported to FDA and described in the literature since these were issued. Individuals who appear to have an increased risk of acute phosphate nephropathy following the use of OSPs include persons over age 55; who are hypovolemic or have decreased intravascular volume; who have baseline kidney disease, bowel obstruction, or active colitis; and who are using medications that affect renal perfusion or function which may include diuretics, angiotensin converting enzyme ACE inhibitors, angiotensin receptor blockers ARBs, and possibly nonsteroidal anti-inflammatory drugs NSAIDs.
If you or a loved one have suffered a kidney injury after using Visicol, OsmoPrep, Fleet Phospho-Soda or any other laxative product or solution containing oral sodium phosphate, you should call our Law Firm immediately. You may be entitled to compensation for your injuries and our Law Firm can help, call 1-800-862-1260.
TRADEMARK NOTICE: Visicol, OsmoPrep, Fleet Phospho-Soda are trademarks of C.B. Fleet Corporation.
The Carabin & Shaw Law Firm, its' lawyers and this website is in no way affiliated with C.B. Fleet Corporation. The use of this mark is solely for informational and product identification purposes.
